Lexington Biosciences Introduces Medical Advisory Board
Advisory team prepares to move HeartSentry through clinical studies
Lexington Biosciences Commences Trading on OTC Markets as LXGTF and Introduces Key Board Members
VANCOUVER, BC — (Marketwired) — 07/06/17 — (CSE: LNB) (CNSX: LNB) (OTC PINK: LXGTF) (the "Company" or "Lexington"), a development-stage medical device company operating within the healthcare industry, is pleased to announce it has met the compliance requirements of the Financial Industry Regulatory Authority (FINRA) and has initiated price quotation on OTC Link under the ticker symbol: LXGTF.In related news, the Company wishes to introduce two members of its Board; Mr. R
Lexington Biosciences Introduces President and Board Chair
VANCOUVER, BC — (Marketwired) — 05/23/17 — (CSE: LNB) (LNB.CN) (CNSX: LNB) (the "Company" or "Lexington"), a development-stage medical device company operating within the healthcare industry, is pleased to introduce and welcome Mr. Eric Willis as Company President, and Mr. Doug Janzen as Board Chairman.Mr. Willis is a twenty plus year veteran of the healthcare technology industry with a passion for working closely with clinicians to bring products from concept to market.